The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Use of Aldosterone Antagonists in Heart Failure
Abstract
CONTEXT: Aldosterone antagonists are recommended for patients with moderate to severe heart failure (HF) and systolic dysfunction. Prior studies suggest underuse of aldosterone antagonists in eligible patients as well as overuse in settings in which therapy may be harmful. OBJECTIVE: To examine aldosterone antagonist prescription based on HF management guideline criteria, investigator-defined appropriateness criteria, and trends over time in patients hospitalized with heart failure. DESIGN, SETTING, AND PATIENTS: Observational analysis of 43,625 patients admitted with HF and discharged home from 241 hospitals participating in the Get With The Guidelines-HF quality improvement registry between January 2005 and December 2007. MAIN OUTCOME MEASURES: Prescription and predictors of use of aldosterone antagonists, based on guideline criteria. RESULTS: Among 12,565 patients eligible for aldosterone antagonist therapy, 4087 (32.5%) received an aldosterone antagonist at discharge, and treatment increased modestly from 28% to 34% over the study period. There was also wide variation in aldosterone antagonist use among hospitals (0%-90.6%). Aldosterone antagonist use in eligible patients was associated with younger age (adjusted odds ratio [OR], 0.85; 95% confidence interval [CI], 0.82-0.88), African American race/ethnicity (adjusted OR, 1.17; 95% CI, 1.04-1.32), lower systolic blood pressure (adjusted OR, 0.94; 95% CI, 0.92-0.95), history of implantable cardioverter-defibrillator use (adjusted OR, 1.51; 95% CI, 1.34-1.69), depression (adjusted OR, 1.15; 95% CI, 1.01-1.30), alcohol use (adjusted OR, 1.23; 95% CI, 1.02-1.50), and pacemaker implantation (adjusted OR, 1.21; 95% CI, 1.06-1.38), and with having no history of renal insufficiency (adjusted OR, 0.85; 95% CI, 0.75-0.96). Applying serum creatinine and potassium appropriateness criteria, inappropriate and potentially inappropriate use of aldosterone antagonist therapy was low and did not change over the 3-year study period. CONCLUSIONS: Less than one-third of eligible patients hospitalized for HF and participating in a quality improvement registry received HF guideline-recommended aldosterone antagonist therapy. Use of aldosterone antagonist therapy among patients with documented contraindications was low.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K.-Y., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Nieminen, M. S., Brutsaert, D., Dickstein, K., Drexler, H., Follath, F., Harjola, V.-P., Hochadel, M., Komajda, M., Lassus, J., Lopez-Sendon, J. L., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl193 · Cited by 1,294
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, B. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035279 · Cited by 640
Hernandez, A. F., Fonarow, G. C., Liang, L., Al-Khatib, S. M., Curtis, L. H., LaBresh, K. A., Yancy, C. W., Albert, N. M., & Peterson, E. D. (2007) · JAMA · doi:10.1001/jama.298.13.1525 · Cited by 419
Self-citationThe American Heart Association get with the guidelines program
Smaha, L. A. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.09.015 · Cited by 292
Cited by
Rehospitalization for Heart Failure
Gheorghiade, M., Vaduganathan, M., Fonarow, G. C., & Bonow, R. O. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.038 · Cited by 730
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J., Christ-Schmidt, H., Berman, L., & Pitt, B. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410853 · Cited by 669
Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2015) · JAMA · doi:10.1001/jama.2015.7446 · Cited by 441
Fonarow, G. C., Albert, N. M., Curtis, A. B., Stough, W. G., Gheorghiade, M., Heywood, J. T., McBride, M. L., Inge, P. J., Mehra, M. R., O'Connor, C. M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.934471 · Cited by 425
Self-citationThe vulnerable phase after hospitalization for heart failure
Greene, S. J., Fonarow, G. C., Vaduganathan, M., Khan, S. S., Butler, J., & Gheorghiade, M. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.14 · Cited by 406
Metadata
- Authors
- Albert, N. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-10-21
- Volume
- 302
- Issue
- 15
- Pages
- 1658
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2023939263
- Cited by
- 262
- References
- 23
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Aldosterone Antagonists in Heart Failure. https://app.cochat.ai/papers/10.1001/jama.2009.1493
- The paper
- Albert, N. M. (2009). Use of Aldosterone Antagonists in Heart Failure. JAMA. https://doi.org/10.1001/jama.2009.1493
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.